Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042935 · ClinicalTrials.gov registry record · Phase 1
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
A Phase 1 study of HNSCC, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04042935 is a Phase 1 study of HNSCC that has completed, run by University of Colorado, Denver. The registered enrollment target is 5 participants, below the 190-participant average among 23 other HNSCC trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04042935, a Phase 1 study of HNSCC, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic acid given during chemotherapy-radiation in HNSCC patients with non-metastatic disease.
Conditions Studied
Interventions
- DRUG Alpha Lipoic Acid
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2021-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042935
The ClinicalTrials.gov registry entry for NCT04042935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 23 other HNSCC trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HNSCC appearing as the primary indexed condition, and to 1 intervention - of which Alpha Lipoic Acid is the first listed.
NCT04042935 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04042935 about?
NCT04042935 is a clinical study titled "Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC". This is a phase I, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic acid given during chemotherapy-radiation in HNSCC patients with non-metastatic disease.
What is the current status of trial NCT04042935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-02-27. Estimated completion is 2021-09-24.
What conditions does trial NCT04042935 study?
This clinical trial studies the following conditions: HNSCC.
What interventions are being tested in trial NCT04042935?
The interventions under investigation include: Alpha Lipoic Acid (DRUG).
Who is sponsoring clinical trial NCT04042935?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04042935 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HNSCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
RECRUITING · Phase 1
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.